Atara Biotherapeutics Announces Proposed Offering of Common Stock
Feb 27, 2018 21:02 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
Feb 27, 2018 21:02 pm UTC| Business
FARMINGTON, Conn., Feb. 27, 2018 -- First Connecticut Bancorp, Inc. (NASDAQ:FBNK) announced that its Board of Directors has voted to increase its quarterly dividend to $0.16 per share, an increase of $0.01. In making...
Teladoc Announces Full Year and Fourth Quarter 2017 Results
Feb 27, 2018 21:02 pm UTC| Business
2017 Revenue of $233.3 million, growth of 89%; 4Q 2017 Revenue of $77.1 million, growth of 106% Total Paid Membership of 23.2 million, growth of 33% 2017 Visits of 1,463,000, growth of 54%; 4Q 2017 Visits of 464,000,...
L.B. Foster Reports Fourth Quarter and Full Year Operating Results
Feb 27, 2018 21:02 pm UTC| Business
PITTSBURGH, Feb. 27, 2018 -- L.B. Foster Company (NASDAQ:FSTR), a leading manufacturer and distributor of products and services for transportation and energy infrastructure, today reported fourth quarter 2017 net income...
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Feb 27, 2018 21:01 pm UTC| Business
– On track to request pre-BLA meeting with FDA in Q2 2018 –– Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 – – Anticipates IND submissions...
McGrath RentCorp Announces Results for Fourth Quarter 2017
Feb 27, 2018 21:01 pm UTC| Business
LIVERMORE, Calif., Feb. 27, 2018 -- McGrath RentCorp (NASDAQ:MGRC) (the “Company”), a diversified business to business rental company, today announced total revenues for the quarter ended December 31, 2017 of $122.2...
Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results
Feb 27, 2018 21:01 pm UTC| Business
Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018 Clinical development of...